Simposi
New Directions In Orphan Drugs For Rare Diseases: From Clinical Trials To Regulatory Paths
27 ottobre 2017 / 8.30-11.00
| 97 |
Innovation in orphan drugs: the regulatory path in Italy Patrizia Popoli (Rome) |
| 98 |
Clinical Research of drugs for rare disease: Issues and open questions Marco Scatigna (Milan) |
| 99 |
Orphan drugs: post-marketing surveillance in Italy Annalisa Capuano (Naples) |
| 100 |
Ethics Committees and orphan drugs: Role and competence of the Ethical Committee for the human clinical investigations in orphan drugs development: procedures for pre-licencing access to the cure of rare diseases Domenico Tricarico (Bari) |
| 101 |
The role of regional coordination networks in patients management and access to therapies Giuseppina Annicchiarico (Bari) |
| 102 |
Role of the cooperation among stakeholders in the development of orphan drugs: the example of inherited rare muscle diseases Sabata Pierno (Bari) |
| 103 |
Olaratumab in rare soft tissue sarcoma Andrea Marrari (Milan) |
| 104 |
Obeticholic acid in primary biliary cholangitis Domenico Alvaro (Rome) |
| 105 |
Stem cells in the treatment of limbal stem cell deficiency Diego Ardigò (Reggio Emilia) |
| 106 |
Recombinant paratyroid hormone and hypoparathyroidism Sabrina Corbetta (Milan) |